An Unlikely Cure Signals New Hope for Cancer
How ‘exceptional responders’ are revolutionizing treatment for the deadly disease
By Kat McGowan
Just like every new drug the oncologists at Memorial Sloan-Kettering Cancer Center tested against bladder cancer in the last 20 years, this one didn’t seem to be doing any good. Forty-four people in the study were given everolimus in a last-ditch attempt to slow down or stop their advanced cancer. When the researchers analyzed the data, they could see that the drug wasn’t slowing or stopping tumor growth. Everolimus seemed to be another bust.
Then there was patient number 45. She joined the trial with advanced metastatic cancer. Tumors had invaded deep into her abdomen, clouding her CT scan with solid grey blotches. She was 73 years old. None of the standard bladder cancer drugs were working for her anymore; she had “failed treatment,” in the dismal lingo of oncologists. She enrolled in the study only because she happened to be a patient at Sloan-Kettering in January 2010. In April 2010, her cancer was gone.
This sort of happy surprise is not unheard of in drug studies. Bodies are fluky, each with its own idiosyncratic combination of genetic blueprints and environmental inputs. So sometimes a patient will be cured by a drug that is useless for…
